Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.
Last trade$8.11
Day change-$0.43 (-5.04%)
Day range$8.03 – $8.74
Volume105,747
Market cap$308M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$308.46M
Price / earnings
—
Price / book
1.74×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.51×
Profitability
Earnings per share
-$1.26
Return on assets
-24.94%
Return on equity
-25.73%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
34×
Quick ratio
34×
Cash ratio
33.68×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.62M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BNTC, quarterly periods
Line item
Q4 FY2026 Jun 30, 2026
Q3 FY2026 Mar 31, 2026
Q2 FY2026 Dec 31, 2025
Q1 FY2026 Sep 30, 2025
Q4 FY2025 Jun 30, 2025
Q3 FY2025 Mar 31, 2025
Q2 FY2025 Dec 31, 2024
Q1 FY2025 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$6.54M
$7.28M
$7.54M
$6.43M
$6.97M
$8.84M
$5.42M
$2.21M
Research and development
$7.89M
$6.3M
$5.83M
$3.37M
$2.87M
$6.5M
$5.39M
$3.59M
Total operating expenses
$14.43M
$13.58M
$13.38M
$9.8M
$9.83M
$15.34M
$10.81M
$5.79M
Operating income
-$14.43M
-$13.58M
-$13.38M
-$9.8M
-$9.83M
-$15.34M
-$10.81M
-$5.79M
Interest expense
$1.57M
$1.59M
$0
$0
$1.04M
$823K
$0
$0
Income before taxes
-$12.81M
-$11.94M
-$11.84M
-$8.97M
-$8.81M
-$14.5M
-$9.55M
-$5.06M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$12.81M
-$11.94M
-$11.84M
-$8.97M
-$8.81M
-$14.5M
-$9.55M
-$5.06M
Net income attributable to common shareholders
-$12.81M
-$11.94M
-$11.84M
-$8.97M
-$8.81M
-$14.5M
-$9.55M
-$5.06M
EBITDA
-$14.41M
-$13.57M
-$13.36M
-$9.79M
-$9.82M
-$15.32M
-$10.79M
-$5.77M
Basic earnings per share
-$0.26
-$0.24
-$0.26
-$0.22
-$0.21
-$0.38
-$0.26
-$0.18
Diluted earnings per share
-$0.26
-$0.24
-$0.26
-$0.22
-$0.21
-$0.38
-$0.26
-$0.18
Recent news
Company coverage with links to the original publishers.
Benitec Biopharma announced completion of 12-month follow-up for all six Cohort 1 patients in its BB-301 Phase 1b/2a trial for oculopharyngeal muscular dystrophy (OPMD)-related dysphagia, with clinically meaningful improvements observed. Cohort 2 is fully enrolled with three patients safely treated. The company held a Type C meeting with the FDA regarding pivotal study design and plans to initiate the pivotal trial in mid-2027. Benitec reported $180 million in cash as of June 30, 2026, with operating expenses of $51.2 million for fiscal year 2026.
Benitec Biopharma announced positive 24-month follow-up results from its BB-301 gene therapy clinical trial for oculopharyngeal muscular dystrophy (OPMD). Patient 1 demonstrated deepening improvements in swallowing function with 60% reduction in post-swallow residue and 78% improvement in dysphagic symptom burden at 24 months. All four patients who completed the 12-month follow-up period met responder criteria, showing durable response to the treatment.
Benitec Biopharma reported positive Phase 1b/2a trial results for BB-301, a gene therapy targeting Oculopharyngeal Muscular Dystrophy (OPMD), with a 100% responder rate. The FDA granted Fast Track Designation, and the company raised $100 million to advance the therapy's development.
Benitec Biopharma will provide an update on its Phase 1b/2a clinical study for BB-301, a gene therapy treatment for Oculopharyngeal Muscular Dystrophy, focusing on results from six patients in Cohort 1.
Benitec Biopharma announced the acceptance of a late-breaking oral abstract for the BB-301 Phase 1b/2a clinical study in Oculopharyngeal Muscular Dystrophy (OPMD) patients. Interim clinical study updates for the first three subjects will be presented at the Muscular Dystrophy Association Clinical and Scientific Conference in March 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.